# A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

> **NCT05446129** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Ezabenlimab
- **DRUG:** BI 765063
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05446129
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-27
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-11-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446129, "A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05446129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*